Product Information:

TIRZEE 7.5mg Pen contains Tirzepatide 7.5mg, a once-weekly dual GIP and GLP-1 receptor agonist used for the treatment of type 2 diabetes mellitus and chronic weight management in adults. Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, leading to enhanced insulin secretion, suppressed glucagon release, slowed gastric emptying, and increased satiety.

The 7.5mg dose is an intermediate-to-high maintenance dose, typically used after successful titration from 2.5mg → 5mg, and offers significant metabolic benefits.

✅ Note: This aligns with globally approved regimens (e.g., Mounjaro®/Zepbound®), where 7.5mg is a standard step in the escalation pathway toward maximal efficacy.

Uses of (TIRZEE 7.5MG PEN):

1. Type 2 diabetes mellitus – for intensified glycemic control
2. Chronic weight management – for sustained appetite suppression and fat loss
3. May improve cardiovascular and renal risk markers in high-risk patients

Key Benefits of (TIRZEE 7.5MG PEN):

1. Once-weekly subcutaneous injection – convenient and adherence-friendly
2. Dual incretin action provides superior HbA1c reduction (up to 2.0–2.3% at this dose)
3. Promotes clinically significant weight loss (average 10–12% body weight)
4. Improves blood pressure, triglycerides, and liver fat
5. Low hypoglycemia risk when not combined with insulin or sulfonylureas

How To Use (TIRZEE 7.5MG PEN):

1. Inject once weekly, on the same day each week, with or without meals.
2. Administer subcutaneously in the abdomen, thigh, or upper arm.
3. Do not inject intravenously or intramuscularly.
4. Dose escalation protocol:
5. Weeks 1–4: 2.5mg once weekly
6. Weeks 5–8: 5mg once weekly
7. Week 9 onward: 7.5mg once weekly
8. May escalate further to 10mg, 12.5mg, or 15mg if needed
9. If a dose is missed, administer within 4 days; if >4 days, skip and resume on the next scheduled day.

When Not to Use (TIRZEE 7.5MG PEN):

Do not use if you have:

1. Personal or family history of medullary thyroid carcinoma (MTC)
2. Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
3. Hypersensitivity to tirzepatide or any excipients
4. Type 1 diabetes or diabetic ketoacidosis

⚠️ Black Box Warning:

Tirzepatide causes thyroid C-cell tumors in rodents. It is contraindicated in patients with MTC risk.

Side Effects of (TIRZEE 7.5MG PEN):

Common (more pronounced than lower doses, but usually transient):

1. Nausea, vomiting, diarrhea, constipation
2. Decreased appetite, abdominal discomfort
3. Fatigue, dizziness
4. Injection site reactions (redness, itching)

Less common:

1. Elevated amylase/lipase levels
2. Gallbladder-related symptoms (biliary colic, cholecystitis)

Serious (rare but require vigilance):

1. Acute pancreatitis (persistent severe upper abdominal pain radiating to back)—discontinue immediately
2. Gallbladder disease (requiring cholecystectomy in some cases)
3. Acute kidney injury (from dehydration due to GI losses)
4. Worsening diabetic retinopathy (in patients with pre-existing proliferative disease)
5. Seek emergency care if severe abdominal pain, vision changes, or persistent vomiting occurs.

Dosage: (TIRZEE 7.5MG PEN):

1. Maintenance dose: 7.5mg once weekly
2. Only initiate after completing ≥4 weeks on 5mg
3. Maximum dose: 15mg once weekly

Who It’s For (TIRZEE 7.5MG PEN):

Adults with type 2 diabetes or obesity who have tolerated lower doses and require stronger glycemic control or weight reduction, and who can manage potential gastrointestinal side effects.

Warnings & Precautions:

1. Ensure adequate daily fluid intake to prevent dehydration
2. Monitor renal function periodically
3. Use caution in patients with history of pancreatitis, gallstones, or diabetic retinopathy
4. Educate on recognizing signs of serious adverse events

Drug Interactions:

1. Insulin or sulfonylureas: ↑ Risk of hypoglycemia—monitor blood glucose closely
2. Oral medications: May delay absorption—administer ≥1 hour before or 4+ hours after tirzepatide
3. Always inform your doctor about all medications and supplements.

Additional Information:

1. Store unused pens refrigerated (2–8°C); after first use, store at room temperature (<30°C) for up to 28 days.
2. Do not freeze. Protect from light.
3. Keep out of reach of children. Available by prescription in Pakistan.